Allergan, Inc.
Allergan, Inc. is a global pharmaceutical company that focuses on developing, manufacturing, and commercializing branded pharmaceuticals, devices, and biologic products. The company was originally incorporated in 1948 as Allergan Pharmaceuticals, Inc., and later changed its name to Allergan, Inc. in 1989. It is headquartered in Dublin, Ireland.
History
Allergan, Inc. was founded by pharmacist Gavin S. Herbert and his partner, chemist Stanley Bly, in 1948. The company initially focused on the production of eye drops and contact lens solutions. In the 1950s, Allergan expanded its product line to include ophthalmic products and later diversified into neurology, dermatology, and aesthetics.
Products
Allergan's product portfolio includes leading brands such as Botox, Juvederm, and Restasis. Botox, a botulinum toxin, is used for various therapeutic and aesthetic treatments. Juvederm is a range of dermal fillers used for facial aesthetics. Restasis is an eye drop used to increase tear production in patients with chronic dry eye.
Acquisitions and Mergers
Over the years, Allergan has been involved in several acquisitions and mergers. In 2015, it was acquired by Actavis plc, a global pharmaceutical company, which subsequently adopted the Allergan name. In 2020, Allergan was acquired by AbbVie, a research-based global biopharmaceutical company.
Research and Development
Allergan's research and development efforts are focused on discovering and developing innovative medicines and therapies. The company has a strong pipeline of potential new products in various stages of development, particularly in the areas of eye care, neurology, and aesthetics.
Controversies
Allergan has faced several controversies, including lawsuits related to the safety and marketing of its products. The company has also been criticized for its pricing practices and for its use of a controversial patent protection strategy involving the Saint Regis Mohawk Tribe.
See Also
Ad. Transform your health with W8MD Weight Loss, Sleep & MedSpa

Tired of being overweight?
Special offer:
Budget GLP-1 weight loss medications
- Semaglutide starting from $29.99/week and up with insurance for visit of $59.99 and up per week self pay.
- Tirzepatide starting from $45.00/week and up (dose dependent) or $69.99/week and up self pay
✔ Same-week appointments, evenings & weekends
Learn more:
- GLP-1 weight loss clinic NYC
- W8MD's NYC medical weight loss
- W8MD Philadelphia GLP-1 shots
- Philadelphia GLP-1 injections
- Affordable GLP-1 shots NYC
|
WikiMD Medical Encyclopedia |
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian

